Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression

[1]  Ming-Wei Yang,et al.  Transcription Factor Profiling to Predict Recurrence-Free Survival in Breast Cancer: Development and Validation of a Nomogram to Optimize Clinical Management , 2020, Frontiers in Genetics.

[2]  Raymond Y Huang,et al.  DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. , 2019, Neuro-oncology.

[3]  G. Sutherland,et al.  Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma , 2018, Oncoimmunology.

[4]  M. Zhou,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[5]  A. Rossi,et al.  Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy , 2018, Therapeutic advances in medical oncology.

[6]  Sandro Santagata,et al.  Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. , 2018, JCO precision oncology.

[7]  Mahlon D. Johnson.  PD-L1 expression in meningiomas , 2018, Journal of Clinical Neuroscience.

[8]  L. Marchionni,et al.  PD‐L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Sachin Kumar,et al.  Epigenetic regulators of programmed death‐ligand 1 expression in human cancers , 2018, Translational research : the journal of laboratory and clinical medicine.

[10]  J. Raizer.  Faculty Opinions recommendation of CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. , 2018 .

[11]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[12]  Eric Faulkner,et al.  PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics , 2018, Diagnostic Pathology.

[13]  E. Hendrick,et al.  PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma , 2018, Oncoimmunology.

[14]  M. Karsy,et al.  Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. , 2017, Journal of neurosurgery.

[15]  R. Dina,et al.  Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior , 2017, Oncoimmunology.

[16]  David M. Jones,et al.  PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry , 2017, Journal of Clinical Pathology.

[17]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[18]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[19]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[20]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[21]  Dong-Wan Kim,et al.  EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3 , 2016, Oncoimmunology.

[22]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  A. Órfão,et al.  Tumor infiltrating immune cells in gliomas and meningiomas , 2016, Brain, Behavior, and Immunity.

[24]  M. Berger,et al.  Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma , 2015, Journal of Neuro-Oncology.

[25]  Zhaoqin Huang,et al.  Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. , 2015, Cancer treatment reviews.

[26]  S. Terry,et al.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. , 2015, American journal of physiology. Cell physiology.

[27]  Anne E Carpenter,et al.  Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma , 2014, Oncotarget.

[28]  P. Wen,et al.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .

[29]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[30]  K. Aldape,et al.  A role for matrix remodelling proteins in invasive and malignant meningiomas , 2014, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[31]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[32]  Yun Bai,et al.  NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment , 2013, PloS one.

[33]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[34]  R. Jensen,et al.  Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. , 2012, Neurosurgery.

[35]  Soheil Shams,et al.  Genomic Landscape of Meningiomas , 2009, Brain pathology.

[36]  Peter J Park,et al.  Specific genes expressed in association with progesterone receptors in meningioma. , 2008, Cancer research.

[37]  S. Vandenberg,et al.  Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas , 2007, Clinical Cancer Research.

[38]  I. Whittle,et al.  The accuracy of meningioma grading: a 10‐year retrospective audit , 2005, Neuropathology and applied neurobiology.

[39]  T. Okazaki,et al.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[41]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[42]  G. Gillespie,et al.  Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. , 1995, Journal of Neurosurgery.

[43]  W. Lee.  Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. , 1990, Neurosurgery.